Biogen (NasdaqGS:BIIB) received Breakthrough Therapy Designation from the FDA for litifilimab in cutaneous lupus ...

Precedence Research, a leading strategic research firm, today released a comprehensive overview of the gene therapy and ...

Biogen's "growth products" — about a half-dozen products including Leqembi — contributed $800 million to the firm's $2.28 ...

Biogen reported positive Phase 2/3 DEVOTE study results for high dose nusinersen in spinal muscular atrophy, published in ...

Biogen Inc. (BIIB) stock reached a 52-week high, peaking at 190.34 USD, underscoring a robust performance over the past year. The stock has experienced a notable 31.14% increase over the last 12 ...

The uptick in Leqembi (lecanemab) sales comes a few months after the FDA approved a once-weekly subcutaneous injection ...

V2X, Inc., , a leading provider of global mission solutions, will report fourth quarter and full year 2025 financial results on Monday, February 23, 2026, after market close. Senior management will ...

("Kneat" or the "Company"), a leader in digitizing and automating validation and quality processes, announced today that the Company will release its financial results for the quarter ended December ...

Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both ...

Biogen CEO Chris Viehbacher joins 'Squawk Box' to discuss the company's 2026 outlook, drug pipeline, the focus on rare diseases, state of the biotech sector, and more. Got a confidential news tip? We ...